187 related articles for article (PubMed ID: 30217378)
1. D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy).
AlKhalfan F; Kerneis M; Nafee T; Yee MK; Chi G; Plotnikov A; Braunwald E; Gibson CM
Am J Cardiol; 2018 Nov; 122(9):1459-1464. PubMed ID: 30217378
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome.
Gibson CM; Mega JL; Burton P; Goto S; Verheugt F; Bode C; Plotnikov A; Sun X; Cook-Bruns N; Braunwald E
Am Heart J; 2011 May; 161(5):815-821.e6. PubMed ID: 21570509
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
Korjian S; Braunwald E; Daaboul Y; Verheugt F; Bode C; Tendera M; Jain P; Plotnikov A; Burton P; Gibson CM
Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):186-193. PubMed ID: 29249166
[TBL] [Abstract][Full Text] [Related]
4. Relation of White Blood Cell Count to Bleeding and Ischemic Events in Patients With Acute Coronary Syndrome (from the ATLAS ACS 2-TIMI 51 Trial).
Alkhalfan F; Nafee T; Yee MK; Chi G; Kalayci A; Plotnikov A; Braunwald E; Gibson CM
Am J Cardiol; 2020 Mar; 125(5):661-669. PubMed ID: 31898965
[TBL] [Abstract][Full Text] [Related]
5. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Mega JL; Braunwald E; Mohanavelu S; Burton P; Poulter R; Misselwitz F; Hricak V; Barnathan ES; Bordes P; Witkowski A; Markov V; Oppenheimer L; Gibson CM;
Lancet; 2009 Jul; 374(9683):29-38. PubMed ID: 19539361
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51).
Mega JL; Braunwald E; Murphy SA; Plotnikov AN; Burton P; Kiss RG; Parkhomenko A; Tendera M; Widimsky P; Gibson CM
J Am Coll Cardiol; 2013 May; 61(18):1853-9. PubMed ID: 23500262
[TBL] [Abstract][Full Text] [Related]
7. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51.
Gibson CM; Chakrabarti AK; Mega J; Bode C; Bassand JP; Verheugt FW; Bhatt DL; Goto S; Cohen M; Mohanavelu S; Burton P; Stone G; Braunwald E;
J Am Coll Cardiol; 2013 Jul; 62(4):286-90. PubMed ID: 23602776
[TBL] [Abstract][Full Text] [Related]
8. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial).
Korjian S; Braunwald E; Daaboul Y; Mi M; Bhatt DL; Verheugt FWA; Cohen M; Bode C; Burton P; Plotnikov AN; Gibson CM
Am J Cardiol; 2018 Dec; 122(11):1896-1901. PubMed ID: 30340765
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
[TBL] [Abstract][Full Text] [Related]
11. The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial.
Cavender MA; Gibson CM; Braunwald E; Wiviott SD; Murphy SA; Toda Kato E; Plotnikov AN; Amuchástegui M; Oude Ophuis T; van Hessen M; Mega JL
Eur Heart J Acute Cardiovasc Care; 2015 Oct; 4(5):468-74. PubMed ID: 25318481
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban: a review of its use in acute coronary syndromes.
Plosker GL
Drugs; 2014 Mar; 74(4):451-64. PubMed ID: 24535922
[TBL] [Abstract][Full Text] [Related]
13. Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome.
Gibson CM; Levitan B; Gibson WJ; Yee MK; Murphy SA; Yuan Z; Chakrabarti AK; Lee M; Braunwald E
J Am Coll Cardiol; 2018 Jul; 72(2):129-136. PubMed ID: 29976285
[TBL] [Abstract][Full Text] [Related]
14. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Reddy P; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
[TBL] [Abstract][Full Text] [Related]
15. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51).
Krantz MJ; Kaul S
J Am Coll Cardiol; 2013 Aug; 62(9):777-81. PubMed ID: 23747777
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51).
Mega JL; Braunwald E; Wiviott SD; Murphy SA; Plotnikov A; Gotcheva N; Ruda M; Gibson CM
Am J Cardiol; 2013 Aug; 112(4):472-8. PubMed ID: 23711804
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pandor A; Pollard D; Chico T; Henderson R; Stevenson M
Pharmacoeconomics; 2016 May; 34(5):463-77. PubMed ID: 26689783
[TBL] [Abstract][Full Text] [Related]
18. Rivaroxaban in acute coronary syndromes--is it prime time?
Asrar ul Haq M; van Gaal WJ
Expert Rev Cardiovasc Ther; 2014 Jun; 12(6):649-58. PubMed ID: 24746010
[TBL] [Abstract][Full Text] [Related]
19. The treatment of missing data in a large cardiovascular clinical outcomes study.
Little RJ; Wang J; Sun X; Tian H; Suh EY; Lee M; Sarich T; Oppenheimer L; Plotnikov A; Wittes J; Cook-Bruns N; Burton P; Gibson CM; Mohanty S
Clin Trials; 2016 Jun; 13(3):344-51. PubMed ID: 26908543
[TBL] [Abstract][Full Text] [Related]
20. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
Becker RC; Alexander JH; Newby LK; Yang H; Barrett Y; Mohan P; Wang J; Harrington RA; Wallentin LC
Thromb Haemost; 2010 Nov; 104(5):976-83. PubMed ID: 20806117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]